Drug repurposing (or repositioning) is an emerging concept to use old drugs for new treatment indications.
Phytochemicals isolated from medicinal plants have been largely neglected in this context, although their pharmacological activities have been well investigated in the past, and they may have considerable potentials for repositioning. A grand number of
plant alkaloids inhibit syngeneic or xenograft
tumor growth in vivo. Molecular modes of action in
cancer cells include induction of cell cycle arrest, intrinsic and extrinsic apoptosis, autophagy, inhibition of angiogenesis and glycolysis, stress and anti-inflammatory responses, regulation of immune functions, cellular differentiation, and inhibition of invasion and
metastasis. Numerous underlying signaling processes are affected by
plant alkaloids. Furthermore,
plant alkaloids suppress
carcinogenesis, indicating chemopreventive properties. Some
plant alkaloids reveal toxicities such as hepato-, nephro- or genotoxicity, which disqualifies them for repositioning purposes. Others even protect from hepatotoxicity or
cardiotoxicity of
xenobiotics and established anticancer drugs. The present survey of the published literature clearly demonstrates that
plant alkaloids have the potential for repositioning in
cancer therapy. Exploitation of the chemical diversity of natural
alkaloids may enrich the candidate pool of compounds for
cancer chemotherapy and -prevention. Their further preclinical and clinical development should follow the same stringent rules as for any other
synthetic drug as well. Prospective randomized, placebo-controlled clinical phase I and II trials should be initiated to unravel the full potential of
plant alkaloids for
drug repositioning.